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Abstract
Objectives: Longitudinal studies examining the baseline predictors of fatigue in SSc have not been reported. Our objectives
were to examine the course of fatigue severity over time and to identify baseline clinical, demographic, and psychosocial
predictors of sequentially obtained fatigue scores in early SSc. We also examined baseline predictors of change in fatigue
severity over time.
Methods: We analyzed 1090 longitudinal Fatigue Severity Scale (FSS) scores belonging to 256 patients who were enrolled in
the Genetics versus Environment in Scleroderma Outcomes Study (GENISOS). Predictive significance of baseline variables for
sequentially obtained FSS scores was examined with generalized linear mixed models. Predictors of change in FSS over time
were examined by adding an interaction term between the baseline variable and time-in-study to the model.
Results: The patients’ mean age was 48.6 years, 47% were Caucasians, and 59% had diffuse cutaneous involvement. The
mean disease duration at enrollment was 2.5 years. The FSS was obtained at enrollment and follow-up visits (mean follow-
up time=3.8 years). Average baseline FSS score was 4.7(60.96). The FSS was relatively stable and did not show a consistent
trend for change over time (p=0.221). In a multivariable model of objective clinical variables, higher Medsger
Gastrointestinal (p=0.006) and Joint (p=0.024) Severity Indices, and anti-U1-RNP antibodies (p=0.024) were independent
predictors of higher FSS. In the final model, ineffective coping skills captured by higher Illness Behavior Questionnaire scores
(p,0.001), higher self-reported pain (p=0.006), and higher Medsger Gastrointestinal Severity Index (p=0.009) at enrollment
were independent predictors of higher longitudinal FSS scores. Baseline DLco % predicted was the only independent
variable that significantly predicted a change in FSS scores over time (p=0.013), with lower DLco levels predicting an
increase in FSS over time.
Conclusions: This study identified potentially modifiable clinical and psychological factors that predict longitudinal fatigue
severity in early SSc.
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Introduction
Systemic sclerosis (scleroderma, SSc) is an autoimmune disease
in which fibrosis of the skin and internal organs occurs in
association with small vessel vasculopathy and autoantibody
production. Organ-specific and non-organ specific impairments
lead to a spectrum of mild to severe limitations in physical, work
and social activities, ultimately influencing health-related quality of
life [1–3]. Fatigue is increasingly recognized as a common
debilitating symptom reported by patients with SSc [4–7]. Fatigue
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26061was rated by SSc patients as the most bothersome symptom [8]. In
a Canadian National survey, SSc patients considered fatigue as
their most prevalent symptom that had at least moderate impact
on activities of daily living [9]. The fatigue severity among SSc
patients is similar to fatigue experienced by patients with
rheumatoid arthritis (RA), ankylosing Spondylitis, and systemic
lupus erythematosus (SLE) [10].
In a large cross sectional study, gastrointestinal (GI) symptoms,
perceived dyspnea, number of comorbidities and current smoking
were significant correlates of four fatigue related items collected as
part of the vitality domain of the SF-36 [4] . To our knowledge,
there are no published longitudinal studies of fatigue severity and
its predictors in SSc.
The pathophysiology of fatigue in chronic diseases is not well
understood, although several causative factors have been identi-
fied. These include anemia, malnutrition, nausea and other GI
symptoms, cytokine imbalance, sleep disturbances, decondition-
ing, lifestyle and psychological factors [11].
In the current study, characteristics of fatigue were prospectively
measured in SSc patients enrolled in the Genetics versus
ENvironment In Scleroderma Outcomes Study (GENISOS)
cohort, using the 29-item Fatigue Severity Scale (FSS) [12]. The
FSS was designed for determining the impact of fatigue symptoms
and severity in chronic diseases and has been extensively utilized in
SLE and multiple sclerosis [12–14].
The objectives of current study were to examine the course of
fatigue severity over time and to identify the baseline demograph-
ic, clinical, and psychosocial factors that predict sequentially
obtained fatigue scores in early SSc. Furthermore, we examined
the predictive significance of the baseline variables for the rate of
change in FSS over time.
Methods
GENISOS is a multicenter prospective study of patients with
early SSc. It is conducted at three sites: the University of Texas
Medical Branch at Galveston (UTMB), the University of Texas
Health Science Center at Houston (UTHSC-H), and the
University of Texas Health Science Center at San Antonio
(UTHSC-SA). Study recruitment started in January 1998 and is
ongoing. The institutional review boards of all participating sites
approved the study and written informed consent was obtained
according to the declaration of Helsinki from all subjects. The
description of the study, cost, risks and discomforts, benefits, and
study withdrawal were included in the informed consent. Study
investigators and coordinators interviewed all study subjects at
each study site.
Patient Selection
Details of patient recruitment have been formerly reported
[15–18]. Patients were enrolled if they met the following criteria:
1) age $18 years; 2) diagnosis according to the American College
of Rheumatology (formerly the American Rheumatism Associa-
tion) criteria or at least 3 of the 5 CREST syndrome features
(Calcinosis, Raynaud’s Phenomenon, Esophageal dysmotility,
Sclerodactyly, Teleangiectasia) ; 3) disease onset (defined as the
time of onset of the first non-Raynaud’s symptom) within five years
of enrollment; and 4) defined ethnicity. All enrolled patients at the
time of analysis were included in this study.
Data collection
As previously described [15–18], the demographic information,
clinical manifestations, patient-reported clinical and psychosocial
data were obtained at the baseline visit and then on subsequent
semi-annual visits.
Outcome variable. Fatigue was ascertained with Fatigue
Severity Scale (FSS), a 29-item validated questionnaire [12] that
reflects how fatigue influences motivation, exercise, physical
functioning, daily activities, interference with work, family, or
social life. Each item is scored on a scale of zero (completely
disagree) to seven (completely agree). A higher score indicates
more fatigue severity. The final score is the average of all scores,
ranging from 0 to 7. Each patient answered the questionnaire at
enrollment and subsequent follow-up visits.
Independent variable. To determine the predictors of fatigue
severity in the course of disease, we investigated a comprehensive
array of potential independent variables from the following domains:
demographic information, clinical manifestations, patient-reported
clinical and psychosocial data.
Demographic information. Age, gender, ethnicity, marital
status, educational level, and health habits were recorded. Marital
status data were dichotomized as being married or in a marriage-
like relationship of cohabitation versus being single, divorced,
separated, or never married. We categorized the educational level
as holding an associate degree (2 years of college education) and
above versus high school diploma and below. Moreover, patients
were interviewed by the study coordinators, about their smoking
and exercise habits, at each visit. Specifically, patients were asked
whether they are currently exercising or smoking cigarettes.
Clinical manifestations. Disease type based on the extent of
skin involvement [19], duration, and antibody profile were recorded.
The disease duration was determined by the study investigators based
on patient interview or review of medical records utilizing two
different methods: from the first non-Raynaud’s phenomenon
symptom attributable to SSc and from the first symptom
attributable to SSc (Raynaud’s or non- Raynaud’s phenomenon
symptoms) to the time of visit. History, physical examination findings,
modified Rodnan Skin Score (mRSS) [20], and Medsger Severity
Index (SI) [21] were recorded. Laboratory studies, EKG, and
pulmonary function tests (PFT) were obtained at enrollment and
annually thereafter. SSc cardiac involvement was defined as having
clinically significant arrhythmia (arrhythmia requiring treatment) or
ejection fraction #40%. All pulmonary function tests were reviewed
by a pulmonologist and studies that did not fulfill the American
Thoracic Society/European Respiratory Society (ATS/ERS) were
excluded [22]. Myositis was diagnosed if the patient had proximal
muscle weakness with at least one of the following: elevated levels of
muscle enzymes, myopathic changes on electromyography, and/or a
characteristic muscle biopsy. Furthermore, we calculated the number
of co-morbid conditions in each patient based on the patients’ history
of cardiovascular disease, hypertension, diabetes mellitus, stroke, lung
disease, malignancy, kidney disease, SLE, RA, thyroid disease,
osteoarthritis, fibromyalgia, peptic ulcer disease, obesity (body mass
index $30), depression, and other neuropsychiatric disorders.
Patient-reported clinical outcomes. We recorded pain and
dyspnea on visual analogue scales (length 10 cm). The anchors of
the VAS were 0 (no pain or shortness of breath) to 100 (very severe
pain or shortness of breath).The severity of symptoms was
measured with a metric ruler in centimeters. A higher score
indicated more severe pain or dyspnea.
Patient-reported dyspnea was investigated only in the univari-
able model. This variable was not included in the subsequent
multivariable models because we assumed that there is a strong bi-
directional relationship between the perceived dyspnea and fatigue
which would inflate the association between those variables.
Patient-reported psychosocial data. We hypothesized
based on previously published studies in SLE [23] and SSc [5]
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fatigue severity. Illness behavior and social support were recorded
by standard psychometric instruments. Coping with disease was
evaluated with the Illness Behavior Questionnaire (IBQ) [24]. IBQ
is a 62-item instrument with a summary score ranging from zero to
35. Higher scores indicate less appropriate illness behaviors. Social
support was assessed by the Interpersonal Support Evaluation List
(ISEL), a 40-item validated instrument with summary score of zero
to ten [25]. Higher scores indicated better social support.
In confirmation of our previous findings [17], Fatigue Severity
Scale and all psychometric instruments demonstrated adequate
internal consistency reliability in the GENISOS cohort. FSS
showed an adequate internal consistency as demonstrated by a
Cronbach’s Alpha value of 0.9. Social support measured by the
ISEL questionnaire had a Cronbach’s Alpha of 0.87. IBQ showed
Cronbach’s Alphas of 0.85.
Statistical analysis
The investigated outcome was the sequentially obtained FSS
scores. We utilized generalized linear mixed models (GLMMS) for
all our analyses to evaluate the effects of the measured baseline
variables on sequentially obtained FSS scores. We treated patients
as a sample from a larger population and modeled between patient
variability in FSS as a random intercept. We also modeled
between patient variability in the change of FSS over time by a
random slope (i.e., we estimated a separate slope for each patient).
We accounted for the correlations among random effect
parameters by an independent covariance matrix. Exchangeable
or unstructured covariance matrices did not improve model fit
evaluated by the Bayesian Information Criterion (BIC). Generally,
mixed-effect models allow inclusion of all data points in the
analysis and can also be used when some data points are missing.
We first investigated the relationship of baseline demographic,
clinical, and psychosocial variables to sequentially obtained FSS in
the univariable model. Subsequently, we built a multivariable
model of objective clinical data. In general, this multivariable
model is less susceptible to problems arising from a bidirectional
relationship between the independent variables and the FSS than
models that include patient-reported independent variables. We
first included all objective clinical variables showing a univariable
association with p,0.1 in the multivariable model. Then, the
number of variables was reduced utilizing a forward hierarchical
variable selection strategy. This variable selection approach was
chosen to decrease the effect of multi-colinearity in our analysis.
We next conducted a hierarchical modeling with successive
conceptual blocks to evaluate whether demographic, clinical and
psychosocial variables independently contribute to FSS. The
independent variables with a p,0.1 in the univariable analysis
were added into the analysis in the following successive conceptual
blocks: demographic variables, objective clinical manifestations,
self-reported clinical outcomes (pain), and psychosocial variables
(Figure S1). The model fit was assessed after addition of each
conceptual block by using Bayesian Information Criterion (BIC).
Lower BIC values indicate better model fit. BIC values are
interpreted as very strong evidence for better fit if the new value is
.10 lower than the previous value. This approach tested the
proposition that each conceptual block independently predicts the
sequentially obtained FSS scores and is not merely a mediator of
the previous variable blocks.
The final multivariable model was built following the above
described forward hierarchical variable selection strategy after
inclusion of relevant demographic, clinical and psychosocial
variables.
We also investigated the predictors of rate of change in FSS over
time. For this purpose, the interaction term of the independent
variable with the time-in-study was investigated. A baseline
variable considered a predictor of change in FSS over time if
the interaction term between the variable and the time-in-study
was significant. The sign and magnitude of the interaction term
coefficient show the direction and magnitude of the change over
time.
All the statistical analyses were performed with STATA 11
(StataCorp, College Station, TX). The hypothesis testing was 2-
sided with a p#0.05 significance level.
Results
Sample characteristics
Between January 1998 and October 2009, 266 patients were
enrolled in the GENISOS cohort. The mean (SD) follow-up time
was 3.8 (3.4) years, ranging up to 11.4 years. The FSS
measurement was not available in 10 patients. In this study,
1090 FSS scores belonging to 256 patients were analyzed. A total
of 213 patients had at least one follow up FSS measurement. Out
of remaining 43 patients, 6 were recent enrollees, 15 died, and 22
were lost to follow up.
The mean age (SD) of patients was 48.6 (13.3) years at
enrollment, 83% were female. The proportions of Caucasian,
African American and Hispanic patients were 47%, 20% and
29%, respectively. About 41% had limited cutaneous involvement.
The mean disease duration (SD) at enrollment was 2.5 (1.6) years.
Table 1 presents the baseline demographic, clinical, psychosocial
characteristics of GENISOS cohort. Further details have been
published previously.
Progression of fatigue over time
At enrollment, the mean FSS (SD) score was 4.7 (0.9), ranging
from 1.1 to 6.6. To determine if FSS scores change over time in
SSc patients, sequentially obtained FSS scores from each
individual in the GENISOS cohort were plotted over time in
Table 1. Population characteristics at baseline study visit.
Age, mean (SD), years 48.6(13.3)
Gender, female, n (%) 221 (83.1)
Ethnicity, n (%)
Caucasian 125 (46.9)
Hispanic 77 (28.9)
African-American 54 (20.3)
Other 10 (3.9)
Disease duration, mean (SD), years 2.5 (1.6)
Cutaneous involvement, diffuse, n (%) 156 (58.6)
Autoantibody profile, n (%)
Anti-centromere antibody 32 (12.0)
Anti-topoisomerase antibody 49 (18.4)
Anti-polymerase III antibody 62 (23.3)
Anti-ribonucleic protein antibody 30 (11.3)
Modified Rodnan Skin Score (MRSS), mean (SD) 15.8 (11.8)
Fatigue Severity Scale (FSS) score, mean (SD) 4.7 (0.9)
Interpersonal Support Evaluation List (ISEL)
score, mean (SD)
8.1 (1.6)
doi:10.1371/journal.pone.0026061.t001
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individuals over time but the FSS levels did not show a consistent
trend of change during the follow up time in the overall cohort.
This was verified by the fact that time-in-study was not associated
with a decline or increase in the sequentially obtained FSS levels
(p=0.221). Figure 2 graphically illustrates that the FSS scores did
not change in 2-year intervals of follow-up time. Furthermore, our
data did not indicate that mortality has influenced the observed
course of fatigue because the vital status (dead versus alive) was
neither predictive of differential levels of serially measured FSS
(p=0.761), nor it was a predictor of change in FSS (p=0.992).
Based on the first and last available FSS measurement, 108
patients (50.7%) showed improved fatigue severity while 103
(48.4%) experienced worsening of fatigue severity. Two patients
(0.9%) had the same FSS level on the last follow up visit. A
minimally clinically important difference (MCID) for FSS has not
been defined for patients with SSc. Therefore, we cannot report
what percentage of patients had a clinically important change in
FSS over time.
Univariable predictors of sequentially obtained FSS
Among demographic variables, only current exercise was a
significant predictor of sequentially obtained FSS scores (negative
relationship) while gender, age, current smoking and ethnicity did
not show a significant relationship to the outcome variable.
The presence of the following baseline clinical variables was a
significant predictor of longitudinal FSS measurements: Diarrhea,
dysphagia, anti-U1 RNP antibody, small joint contracture, higher
serum creatinine level, and higher Medsger Gastrointestinal Index
were associated with higher sequentially obtained FSS scores
(increasing fatigue severity).
Both patient-reported clinical outcomes (VAS pain and
dyspnea) were also associated with higher FSS. Among baseline
psychosocial measures, maladaptive behavior (higher IBQ) was a
significant predictor of higher longitudinal FSS scores. Detailed
results of univariable analyses are shown in Table 2 and Table S1.
Independent clinical predictors of sequentially obtained
FSS
We next identified independent objective clinical correlates of
sequentially obtained FSS, utilizing a forward hierarchical variable
selection. In this multivariable analysis, higher Medsger Gastro-
intestinal (p=0.006) and Joint (p=0.024) Severity Indices and
presence of anti-U1 RNP antibodies (p=0.024) were independent
predictors of higher FSS (Table 3).
Successive conceptual blocks predicting sequentially
obtained FSS
We next examined the predictive significance of baseline
characteristics grouped in the following conceptual blocks: 1)
demographic; 2) objective clinical manifestations; 3) patient-
reported clinical outcomes; 4) psychosocial variables. In the
following models, only the baseline variables were included that
predicted the longitudinal FSS with p-values,0.1 in the univari-
able analysis. The results of this successive conceptual block
modeling are shown in Figure S1 and Table S2.
In model 1, the relevant demographic variables were examined.
This model had a BIC of 2381 (p=0.007). In model 2, the
relevant clinical variables were added to the previous model which
resulted in an improved BIC of 2181 (delta=200, p,0.001). This
indicated that the addition of objective clinical variables led to a
substantially better model fit. In model 3, we added the patient-
reported clinical outcome, VAS for pain to the previous two
blocks. This model also resulted in a better model fit as indicated
by a BIC of 2132 (delta=49, p,0.001). The VAS dyspnea was
not included in this model because of concerns regarding a strong
bidirectional relationship between perceived dyspnea and fatigue
severity. In the last model, the relevant patient-reported
psychosocial data were added to the previous conceptual blocks.
Model 4 had the lowest BIC (2117) and showed a strong evidence
for better model fit compared to Model 3 (delta=15, p,0.001).
This blockwise hierarchical modeling strategy indicated that
each successive block (demographic, objective clinical, patient-
Figure 1. Course of Fatigue Severity Scale (FSS) scores in individual patients followed in the GENISOS cohort. X axis: follow-up time in
days; Y axis: FSS scores.
doi:10.1371/journal.pone.0026061.g001
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predictive significance for sequentially obtained FSS and was not
merely a mediator of previous blocks.
Independent predictors of sequentially obtained FSS
(final model)
All relevant demographic, clinical, and psychosocial variables
were included in the final model (Table 4). Following a forward
variable selection strategy, VAS for pain (p=0.006), maladaptive
coping skills captured by higher IBQ score (p,0.001), and
Medsger Gastrointestinal Severity Index (p=0.009) were inde-
pendent predictors of higher sequentially obtained FSS scores.
Predictor of rate of change in FSS over time
In the last step, we investigated the predictive significance of
baseline variables for rate of change in FSS over time. As shown in
Table 2 and Table S1, patient’s baseline DLco% predicted level
was the only significant predictor of change in FSS over time
(p=0.013). Patients with higher DLco% predicted levels had a
decline in FSS whereas patients with lower DLco% predicted
levels experienced an increase in FSS over time. Similar trends
were observed for baseline FVC% predicted (p=0.06).
Discussion
In this study, we examined the course of fatigue severity in a
large, multi-ethnic cohort of early SSc patients. To our knowledge,
the current study represents the first longitudinal examination of
fatigue in SSc. FSS levels did not increase or decrease during the
follow up time in the overall cohort, though patients with lower
baseline DLco levels experienced an increase in their fatigue
severity over time. Demographic, clinical, and psychosocial
variables were all independent predictors of sequentially obtained
FSS scores. Severity of GI and joint involvement and presence of
anti-U1 RNP antibodies were independent predictors of FSS in
the multivariable model of clinical factors. Baseline perceived pain
levels, coping skills (IBQ), and GI involvement were independent
predictors of longitudinal FSS in the final extended multivariable
model.
Higher baseline scores of the Medsger Gastrointestinal Severity
Index were predictive of higher FSS scores. This supports a
reported association of GI involvement and higher fatigue scores
in a cross sectional study of SSc patients [4]. GI involvement is
very common in SSc patients and its strong association with
depression has been previously reported [26,27]. The association
of GI dysmotility with fatigue severity may have several direct and
indirect causes. Patients with diarrhea and decreased intestinal
absorption might develop nutritional deficiencies with subsequent
muscular and electrolyte abnormalities. Moreover, diarrhea and
abdominal pain might interfere with sleep, resulting in higher
fatigue scores. In patients with chronic fatigue syndrome,
abdominal pain was stressful, but nocturnal diarrhea was found
to further disrupt an already disrupted sleep pattern [28]. Fatigue
is also a prominent feature of autoimmune diseases with primary
GI manifestation such as Crohn’s disease. In a randomized
controlled study examining the effects of adalimumab therapy in
patients with moderate to severe Crohn’s disease, adalimumab
maintenance therapy provided sustained improvement in fatigue
severity compared to conventional immunosuppressive therapy
[29].
In the current study, higher Medsger Joint Severity Index
predicted higher FSS scores. The role of joint involvement as
contributor to fatigue severity in SSc has not been previously
reported. However, fatigue is also a prominent feature of other
autoimmune diseases that primarily affect joints such as rheuma-
toid arthritis (RA) [30]. The effect of conventional disease
modifying antirheumatic drugs (DMARD) on fatigue severity
compared to placebo in RA has not been investigated but a
Figure 2. Course of Fatigue Severity Scale (FSS) scores over 2 year intervals of follow up time. Data are presented in box plots. Each box
represents the 25th to 75th percentile. The length of the box is the interquartile range (IQR). The line inside the box represents the median. Whiskers
reprsent 1.5 times the upper and lower IQRs. Circles indicate individual outliers. N is the number of patients who had at least one FSS measurement
during the time interval.
doi:10.1371/journal.pone.0026061.g002
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variables.
Main effect Interaction between independent variable and time-in-study
Independent Variable b (95% CI) p-value b (95% CI) p-value
Follow-up time 20.01 (20.04, 0.01) 0.221
Demographic
Age 0.01 (20.01, 0.01) 0.793 0.01 (20.01,0.01) 0.31
Gender, female 0.08 (20.20, 0.35) 0.579 20.03(20.09, 0.02) 0.255
Ethnicity, Caucasian 0.17 (20.04, 0.37) 0.111 0.02(20.02, 0.07) 0.287
Exercise habits 20.31 (20.52, 20.09) 0.004 0.02 (20.02, 0.07) 0.367
Marital Status 20.18 (20.3820.03) 0.093 0.01 (20.04, 0.05) 0.919
Clinical manifestations
Disease duration 0.01 (20.05, 0.08) 0.658 0.01 (20.01, 0.02) 0.752
Diffuse cutaneous involvement 20.20 (20.41, 0.01) 0.059 20.01 (20.05, 0.04) 0.971
Dysphagia 0.27 (0.07, 0.47) 0.009 20.03 (20.07, 0.02) 0.232
Diarrhea 0.28 (0.08, 0.48) 0.006 20.03 (20.07, 0.02) 0.221
BMI
* 0.01 (20.01, 0.02) 0.554 0.01 (20.01, 0.01) 0.401
Small joint contracture 0.32 (0.05, 0.59) 0.021 20.02 (20.08, 0.04) 0.587
mRSS
** 0.01 (20.01, 0.02) 0.251 20.01 (20.01, 0.01) 0.947
No of comorbidities 0.06 (20.01, 0.12) 0.089 0.01 (20.01, 0.02) 0.954
Serum creatinine level 0.19 (0.02, 0.36) 0.033 20.01 (20.07, 0.06) 0.928
Hematocrit 0.01 (20.02, 0.03) 0.889 0.01 (20.01, 0.01) 0.106
Cardiac involvement 0.31 (20.01, 0.62) 0.051 20.02 (20.1, 0.05) 0.538
Antibody profile
Anti-centromere antibody 20.16 (20.47, 0.16) 0.329 0.01(20.06, 0.08) 0.782
Anti-topoisomerase antibody 20.12 (20.39, 0.14) 0.359 0.03 (20.03, 0.09) 0.298
Anti-polymerase III antibody 0.04 (20.20, 0.27) 0.774 0.01 (20.05, 0.05) 0.948
U1-RNP 0.42 (0.09, 0.74) 0.012 20.04 (20.12, 0.04) 0.376
FVC
{ % predicted value 20.01 (20.01, 0.01) 0.204 20.01 (20.01, 0.01) 0.06
DLco
{ % predicted value 20.01 (20.01, 0.01) 0.135 20.01 (20.01, 0) 0.013
Medsger Severity Index
General 0.02 (20.11, 0.15) 0.721 0.01 (20.03, 0.03) 0.969
Perivascular 0.01 (20.09, 0.10) 0.956 20.01 (20.03, 0.12) 0.447
Skin 0.07 (20.05, 0.19) 0.259 0.01 (20.03, 0.03) 0.992
Joint 0.08 (20.01, 0.16) 0.059 0.01 (20.02, 0.02) 0.915
Muscle 0.19 (20.06, 0.43) 0.133 0.01 (20.04, 0.06) 0.713
GI Tract 0.23 (0.08, 0.39) 0.004 0.01 (20.4, 0.05) 0.819
Lung 0.04 (20.05, 0.14) 0.346 0.01 (20.01, 0.03) 0.250
Heart 0.06 (20.09, 0.19) 0.439 0.03 (20.01, 0.07) 0.208
Kidney 0.20 (20.03, 0.44) 0.090 0.06 (20.03, 0.15) 0.21
Patient-reported clinical outcome
VAS
b for pain 0.06 (0.03, 0.09) ,0.001 20.01 (20.01, 0.01) 0.522
VASb for dypnea 0.09 (0.05, 0.12) ,0.001 20.01 (20.01, 0.01) 0.994
Psychosocial measures
IBQ
V 0.06 (0.04, 0.08) ,0.001 20.01 (20.01, 0.01) 0.093
ISEL
Y 20.01 (20.08, 0.06) 0.787 20.01 (20.02, 0.02) 0.959
*BMI: Body mass index;
**mRSS: modified Rodnan Skin Score;
{FVC: Forced vital capacity;
{DLco: Diffuse capacity of the lung for carbon monoxide;
bVAS: Visual Analogue Scale;
VIBQ: Illness Behavior Questionnaire;
YISEL: Interpersonal Support Evaluation List.
doi:10.1371/journal.pone.0026061.t002
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moderate to severe RA was reported with adalimumab treatment
compared to conventional DMARD therapy [31]. Furthermore,
aerobic exercise, with most regimens consisting of 3 times weekly
for 30–60 minutes exercises, was effective in treatment of fatigue
in patients with RA (reviewed in [32]). Similar to RA, exercise
habits were the only demographic variable predictive of fatigue
severity in our study. This finding supports future interventional
studies examining the efficacy of exercise regimens for treatment of
fatigue in SSc.
Presence of U1-RNP antibodies were predictive of higher
sequentially obtained FSS levels. Autoantibodies are important
predictors of various disease manifestations in SSc [33,34]. The
association of SSc-related antibodies with fatigue severity has not
been examined in previous publications. The U1-RNP antibodies
are associated with overlap cases of SSc with other connective
tissue diseases such as SLE and polymyositis. It is possible that
experiencing features of multiple connective tissue diseases can
lead to more severe fatigue.
In the final model, two patient-reported outcomes (pain and
IBQ) were predictive of higher FSS levels. The blockwise
hierarchical analysis indicated that patient-reported variables
contributed to fatigue beyond the effect of clinical and demo-
graphic factors. Although the relationship of the patient-reported
variables to FSS might be bidirectional (e.g. pain and IBQ
influence FSS and vice versa). The reported multivariable model
with objective clinical variables is least susceptible to problems
arising from the bidirectional relationship between the predictor
and outcome variables. However, we did not confine our study to
objective clinical predictors because this would have ignored
important subjective determinants of FSS. Furthermore, we did
not only investigate the relationship of the above mentioned
independent variables with the concomitantly obtained FSS levels
but we also investigated whether they have predictive significance
for FFS levels obtained on subsequent visits.
Inappropriate illness behavior (coping) captured by a higher
IBQ score was an independent predictor of longitudinal FSS. The
IBQ assesses a spectrum of illness behaviors or modes of
perceiving, evaluating, or acting in relation to one’s own state of
health that may be in contradistinction to an accurate appraisal of
the condition and prescribed treatment [24]. Similar to our results,
the LUMINA study has demonstrated the association of higher
IBQ scores with higher scores of perceived fatigue in SLE [23].
Furthermore, it has also been shown that higher IBQ scores
reflecting worse coping behavior can affect the quality of life in
SLE patients [14] . In patients with RA, group cognitive
behavioral therapy for fatigue self-management (coping) was
found be effective in treating fatigue severity in a recently
published randomized controlled trial [35]. Our study provides
further support for similar interventional studies in SSc, examining
the efficacy of self management and coping strategies for treatment
of fatigue.
Pain was another patient-reported variable that predicted
higher FSS levels in our study. This finding is in agreement with
longitudinal studies of fatigue in patient with SLE [23]. Pain in
SSc can be caused by various disease manifestations such as joint
pain, digital ulcer, heartburn, and tendon friction rub [36]. Better
treatment of pain and more effective management of its
underlying causes might alleviate fatigue severity in patient with
SSc.
FSS scores did not increase or decrease during the follow up
time in the overall cohort. Factors leading to worsening fatigue
such as increasing age and disease damage might be counterbal-
anced by improving adaptive behaviors leading to stable
longitudinal fatigue severity in SSc. A study of a longitudinal
cohort of 122 patients with RA also reported that FSS scores did
not change appreciably over time [37]. Furthermore, studies in
patients with chronic fatigue syndrome indicated that patients with
longer disease duration had better adaptive coping strategies than
those with shorter disease duration, supporting the hypothesis that
patients with chronic illnesses develop better coping skills for
dealing with fatigue over time. Another possible explanation for
stable longitudinal fatigue levels is that fatigue might be related to
inherent perceived health or coping mechanisms. Although the
success of exercise regimens [32], behavioral [35] and pharma-
cological [29,31] interventions for treatment of fatigue in other
rheumatic diseases indicates that this disease manifestation is
modifiable and not solely related to related inherent and non-
modifiable patient characteristics.
DLco% predicted was the only baseline variable that was
predictive of change in fatigue severity. A similar trend was
observed for FVC although it did not reach statistical significance.
This finding indicates that patients with more extensive lung
involvement are more likely to experience an increase in their
fatigue levels over time. Several medications are effective in
treatment of pulmonary arterial hypertension (reviewed in [38] )
and cyclophosphamide is beneficial for treatment of interstitial
lung disease in SSc [39]. It is unclear whether treatment with these
agents can lead to a reduction in fatigue severity in SSc.
Furthermore, the role of pulmonary rehabilitation in treatment
of lung impairment and fatigue also has not been investigated in
SSc. In patients with chronic obstructive pulmonary disease,
pulmonary rehabilitation for 3 months was effective for treatment
of dyspnea and fatigue [40].
The current study had some limitations. The majority of study
subjects were recruited from tertiary medical centers, which might
skew the study population toward patients with more severe
Table 3. Multivariable analysis of objective clinical predictors
of sequentially obtained FSS.
Regression
coefficient (95% CI) p-value
Medsger Severity Index - GI tract 0.22 (0.06, 0.38) 0.006
Medsger Severity Index - Joint 0.09 (0.01, 0.17) 0.024
U1-RNP* 0.37 (0.05, 0.7) 0.024
*U1-RNP: Anti-U1 ribonucleoprotein antibodies.
doi:10.1371/journal.pone.0026061.t003
Table 4. Multivariable analysis of independent
demographics, clinical, and patient-reported clinical outcome,
and psychosocial predictors of longitudinally obtained FSS
scores.
Regression
coefficient (95% CI) p-value
VAS* for pain 0.04 (0.01, 0.07) 0.006
IBQ** 0.05 (0.03, 0.07) ,0.001
Medsger Severity Index - GI tract 0.2 (0.05, 0.35) 0.009
*VAS: Visual Analogue Scale.
**IBQ: Illness behavior questionnaire.
doi:10.1371/journal.pone.0026061.t004
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26061involvement. Furthermore, we did not have information on sleep
disturbances in the GENISOS cohort, a factor that might be an
independent predictor of fatigue in SSc. Furthermore, we did not
use a designated questionnaire for capturing depressive symptoms
in the GENISOS.
Fatigue is a prominent and debilitating problem for a large
number of SSc patients. Our results indicate that potentially
modifiable clinical and psychological factors predict longitudinal
fatigue severity. Measures to decrease physical burden of disease
such as respiratory, GI and joint involvement, as well as
interventions focusing on improving coping skills and pain could
potentially improve fatigue severity in SSc.
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